Rani Therapeutics Holdings, Inc. (RANI) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...
Rani Therapeutics Holdings, Inc. (RANI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions...
SAN JOSE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”) (Nasdaq: RANI), a clinical-stage...
- Announced positive topline Phase 1 results of RT-102 for the treatment of osteoporosis - - Anticipate initiating an additional Phase 1 clinical trial in...
- RT-102 was generally well-tolerated, with no RaniPill™-related adverse events - - Bioavailability of PTH delivered via the RaniPill was found to be...
Extends Rani’s projected cash runway into mid-2024...
Axsome's (AXSM) extension of the review period for AXS-05 NDA and CRL for AXS-07 NDA hurt prospects. However, recent positive updates on AXS-05 are driving positive sentiments.
- Initiated a Phase 1 clinical trial of RT-102 for the treatment of osteoporosis – - Unveiled the high-capacity RaniPill™ HC, capable of delivering...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...
SAN JOSE, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage...